TenNor held a kick-off meeting for the phase II clinical trial of TNP-2092 IV in San Francisco on Aug. 2, 2018. This product has been developed to solve the challenges of bacterial biofilm infections associated with implantable medical devices in clinic. The phase II trial will further evaluate the safety and effectiveness of the drug candidate. TNP-2092 is a multi-targeting New Molecular Entity specifically designed for the treatment of infections associated with bacterial biofilms and significantly differentiated from the current treatments. The compound exhibited potent activity against the major pathogens for the infections on implanted medical devices, including those that are resistant to the market antibiotics, and showed low propensity for the development of drug resistance. The compound also demonstrated excellent activity in multiple in vitro and in vivo biofilm models. ‘This project is an important part of our overall clinical plan based on the full communications with the FDA’, said Xiaomei Wang, VP of Clinical Operation in TenNor, ‘Successful development of TNP-2092 is expected to address unmet clinical needs in the field of anti-infections and has application prospect in the treatment of various medical device-associated infections.’
The 9th China Healthcare Investment Conference (CHIC) was held on March 28-29, 2018 in Shanghai. Dr. Zhenkun Ma, Founder and CEO of TenNor Therapeutics, presented TenNor’s recent progress to the conference (please click this link for the presentation: TENNOR 9th CHIC Presentation). CHIC is the premier investment conference in China. In 2010, recognizing that the healthcare reform and industry growth was spurring a new wave of emerging Chinese healthcare companies, a group of investors led the efforts to organize China Healthcare Investment Conference. This prestigious event has since grown into the most powerful platform to promote and nurture the Chinese healthcare investment ecosystem and further develop the industry.
TenNor Therapeutics held its first Clinical Advisory Meeting on TNP-2092 for the treatment of prosthetic joint infections (PJIs) during the American Association of Hip and Knee Surgeons (AAHKS) Meeting in San Francisco on May 5, 2017. The meeting was chaired by Dr. Javad Parvizi, MD, from the Rothman Institute who is a world leading expert in the management of PJIs. The meeting was attended in person or by phone by seven other opinion leaders in the field. Dr. Zhenkun Ma, PhD, Founder and CEO, presented the background information on TNP-2092 and Dr. Martino Laurenzi, MD, Chief Medical Officer, presented the clinical development plan and study protocols. On behalf of TenNor, Xiaomei Wang, Head of Clinical Operation, Dr. Mark Goldberger, MD, regulatory consultant and Aaron Dane, statistician and clinical development consultant also attended the meeting. Treatment of PJIs is one of the major unmet medical needs in the infectious disease area. With population aging, the number of total hip and knee replacement surgeries is increasing rapidly and projected to reach 4 million by 2030 in the United States. Despite the best prevention efforts, the incidence rate for PJIs remains 1-3%. PJIs are difficult to treat, often requiring implant replacement surgery accompanied by prolonged antibiotic therapy. PJIs are a major health problem for the patients and associated with high cost to the healthcare system. TNP-2092 is a multi-targeting antibacterial agent with potent activity against major pathogens associated with PJIs living in bacterial biofilms. It has the potential to improve the management of PJIs and is currently under clinical development by TenNor. The Advisory Group is encouraged by the development of TNP-2092 and provided valuable inputs to the clinical development plan and to the PJI study protocol.